WHAT IS CLAIMED IS:

1	1. A method of determining the ability of a Mycobacterium	
2	tuberculosis bacterium to oxidize a thioamide or a thiocarbonyl, said method comprising	
3	detecting a mutation in an EtaA gene (SEQ ID NO:1) in said bacterium, wherein	
4	detection of the mutation is indicative of decreased ability to oxidize a thioamide or a	
5	thiocarbonyl.	
1	2. The method of claim 1, wherein the mutation is a frameshift	
1	mutation selected from the group consisting of: a deletion at position 65, an addition at	
2	position 567, and an addition at position 811.	
3	•	
1	 The method of claim 1, wherein the mutation is a single nucleotide 	
2	polymorphism which causes an amino acid substitution in an amino acid sequence	
3	encoded by said EtaA gene compared to an amino acid sequence of SEQ ID NO:2.	
	4. The method of claim 3, wherein the single nucleotide	
1	4. The method of claim 3, wherein the single nucleotide polymorphism causes an amino acid substitution selected from the group consisting of:	
2		
3	G43C, P51L, D58A, Y84D, T186K, T342K, and A381P.	
1	 A method of claim 1 wherein the mutation is detected by 	
2	(a) amplifying the EtaA gene, or a portion thereof containing the	
3	mutation, with a set of primers to provide an amplified product,	
4	(b) sequencing the amplified product to obtain a sequence, and	
5	(c) comparing the sequence of the amplified product with the	
6	sequence of a wild-type EtaA gene (SEQ ID NO:1) or portion thereof,	
7	wherein a difference between the sequence of the amplified product and the sequence of	
8	the wild-type EtaA gene or portion thereof indicates the presence of a mutation.	
1	6. A method of claim 5, wherein at least one of said primers is	
2	selected from the group consisting of:	
3	5'-GGGGTACCGACATTACGTTGATAGCGTGGA-3' (SEQ ID NO:3),	
4	5'-ATAAGAATGCGGCCGCAACCGTCGCTAAAGCTAAACC-3' (SEQ ID NO:4),	
5	5' ATCATCCATCCGCAGCAC 3' (SEQ ID NO:5);	
6	5' AAGCTGCAGGTTCAACC 3' (SEQ ID NO:6);	
7	5' GCATCGTGACGTGCTTG 3' (SEQ ID NO:7);	

5

5' AAGCTGCAGGTTCAACC 3' (SEQ ID NO:8); 8 5' TGAACTCAGGTCGCGAAC 3' (SEQ ID NO:9); 9 5' AACATCGTCGTGATCGG 3' (SEQ ID NO:10); 10 5' ATTTGTTCCGTTATCCC 3' (SEQ ID NO:11); 11 5' AACCTAGCGTGTACATG 3' (SEQ ID NO:12); 12 5' TCTATTTCCCATCCAAG 3 (SEQ ID NO:13); and 13 5' GCCATGTCGGCTTGATTG 3' (SEQ ID NO:14). 14 A method of claim 5, wherein the primers are 1 7. 5'-GGGGTACCGACATTACGTTGATAGCGTGGA-3' (SEQ ID NO:3), and 2 5'-ATAAGAATGCGGCCGCAACCGTCGCTAAAGCTAAACC-3' (SEQ ID NO:4). 3 A method of claim 5, wherein said amplification is by polymerase 1 2 chain reaction. A method of claim 1, wherein said mutation is detected by hybridizing DNA from said bacterium to a test nucleic acid under stringent conditions. 2 A method of claim 9, wherein either said DNA from said bacterium 1 10. or said test nucleic acid is immobilized on a solid support. 2 A method of claim 1, wherein said mutation is detected by 1 11. (a) subjecting said EtaA gene to digestion by restriction enzymes, 2 (b) separating the resulting restriction products to form a pattern of 3 restriction fragment lengths, and 4 (c) comparing the pattern of restriction fragment lengths to a 5 pattern of restriction fragment lengths formed by subjecting a known EtaA gene to the 6 7 same restriction enzymes. A method of claim 11, wherein said known EtaA gene is selected 12. 1 from the group consisting of (a) a frameshift mutation consisting of a deletion at position 2 65, an addition at position 567, and an addition at position 811, and (b) a single 3 nucleotide polymorphism which causes an amino acid substitution selected from the 4

group consisting of: G43C, P51L, D58A, Y84D, T186K, T342K, and A381P.

1	13. A method of claim 1, wherein said mutation is detected by
2	specifically binding an antibody to a mutated product of the EtaA gene, wherein the
3	specific binding of the antibody to the mutated gene product is indicative of a mutation
4	which inhibits the ability of the bacterium to oxidize a thioamide.
1	14. A method of claim 13, wherein said gene product is in, or is
2	isolated from, sputum.
1	15. A method of claim 13, wherein detection of said specific binding of
	said antibody and said mutated gene product is by ELISA.
2	said antibody and said initiated gene product is by EEDIOT.
1	16. A method of claim 1, wherein said thioamide or thiocarbonyl is
2	selected from the group consisting of ethionamide, thiacetazone, and thiocarlide.
1	17. A method of claim 1, wherein said mutation is detected by
2	(a) culturing said bacterium in the presence of ethionamide; and
3	(b) testing for the presence or absence of (2-ethyl-pyridin-4-yl)methanol,
4	wherein the absence of (2-ethyl-pyridin-4-yl)methanol indicates that the bacterium has a
5	mutation which is indicative of decreased ability to oxidize a thioamide.
	A method of claim 17 wherein the presence or absence of (2-ethyl-
1	pyridin-4-yl)methanol is tested by subjecting a medium in which the bacterium is
2	cultured, or the bacterium, to analysis by thin-layer chromatography, high pressure liquid
3	
4	chromatography, or mass spectrometry.
1	19 A method of claim 17, wherein the ethionamide of step (a) is
2	radioactively labeled.
	•
1	A method of claim 17, wherein the (2-ethyl-pyridin-4-yl)methanol
2	is radioactively labeled.
	21. A method of screening an individual for a Mycobacterium
1	tuberculosis bacterium resistant to treatment by a thioamide or a thiocarbonyl drug,
2	
3	comprising
4	(a) obtaining a biological sample containing said bacterium from said
5	individual, and

6	(b) det	ecting a mutation in an EtaA gene (SEQ ID NO:1) in said	
7	bacterium, wherein detection of the mutation is indicative said bacterium is resistant to		
8		ide or a thiocarbonyl drug.	
		and a contract of the contract of the detected by	
1	22.	A method of claim 21, wherein the mutation is detected by	
2		(a) amplifying the EtaA gene with a set of primers to provide an	
3	amplified product,		
4		(b) sequencing the amplified product to obtain a sequence, and	
5		(c) comparing the sequence of the amplified product with the	
6	sequence of a wild-type EtaA gene (SEQ ID NO:1),		
7		n a difference between the sequence of the amplified product and	
8	the sequence of the w	ild-type EtaA gene indicates the presence of a mutation.	
1	23.	A method of claim 21, wherein at least one of said primers is	
2	selected from the gro		
3		CATTACGTTGATAGCGTGGA-3' (SEQ ID NO:3),	
4	5'-ATAAGAATGC	GGCCGCAACCGTCGCTAAAGCTAAACC-3' (SEQ ID NO:4), 5'	
5	ATCATCCATCCGC	CAGCAC 3' (SEQ ID NO:5);	
6	5' AAGCTGCAGGT	TCAACC 3' (SEQ ID NO:6);	
7	5' GCATCGTGACC	TGCTTG 3' (SEQ ID NO:7);	
8	5' AAGCTGCAGG	TTCAACC 3' (SEQ ID NO:8);	
9		CGCGAAC 3' (SEQ ID NO:9);	
10		GATCGG 3' (SEQ ID NO:10);	
11	5' ATTTGTTCCGT	TATCCC 3' (SEQ ID NO:11);	
12	5' AACCTAGCGTO	GTACATG 3' (SEQ ID NO:12);	
13		TCCAAG 3 (SEQ ID NO:13); and	
14		CTTGATTG 3' (SEQ ID NO:14).	
1	24.	A method of claim 21, wherein said primers are	
2	5'-GGGGTACCGA	CATTACGTTGATAGCGTGGA-3' (SEQ ID NO:3) and 5'-	
3		CCGCAACCGTCGCTAAAGCTAAACC-3' (SEQ ID NO:4).	
1	25.	A kit for determining the ability of a Mycobacterium tuberculosis	
2		a thioamide or a thiocarbonyl, the kit comprising:	
3		container, and	
	(4) 4		

4	(b) primers for amplifying an EtaA gene of said bacterium or a portion of		
5	said EtaA gene containing a mutation affecting the ability of the bacterium to oxidize a		
6	thioamide.		
	26. A kit of claim 25, wherein at least one of said primers is selected		
1			
2	from the group consisting of:		
3	5'-GGGGTACCGACATTACGTTGATAGCGTGGA-3' (SEQ ID NO:3),		
4	5'-ATAAGAATGCGGCCGCAACCGTCGCTAAAGCTAAACC-3' (SEQ ID NO:4),		
5	5' ATCATCCATCCGCAGCAC 3' (SEQ ID NO:5);		
6	5' AAGCTGCAGGTTCAACC 3' (SEQ ID NO:6);		
7	5' GCATCGTGACGTGCTTG 3' (SEQ ID NO:7);		
8	5' AAGCTGCAGGTTCAACC 3' (SEQ ID NO:8);		
9	5' TGAACTCAGGTCGCGAAC 3' (SEQ ID NO:9);		
10	5' AACATCGTCGTGATCGG 3' (SEQ ID NO:10);		
11	5' ATTTGTTCCGTTATCCC 3' (SEQ ID NO:11);		
12	5' AACCTAGCGTGTACATG 3' (SEQ ID NO:12);		
13	5' TCTATTTCCCATCCAAG 3 (SEQ ID NO:13); and		
14	5' GCCATGTCGGCTTGATTG 3' (SEQ ID NO:14).		
1	27. A kit of claim 25, wherein the primers are		
2	5'-GGGGTACCGACATTACGTTGATAGCGTGGA-3' (SEQ ID NO:3), and		
3	5'-ATAAGAATGCGGCCGCAACCGTCGCTAAAGCTAAACC-3' (SEQ ID NO:4).		
-			
1	28. A kit of claim 25, further comprising a mutated EtaA gene for use		
2	as a positive control.		
1	29. A kit of claim 28, wherein said mutated EtaA gene is selected from		
2	the group consisting of (a) a frameshift mutation consisting of a deletion at position 65, as		
3	addition at position 567, and an addition at position 811, and (b) a single nucleotide		
4	polymorphism which causes an amino acid substitution selected from the group		
5	consisting of: G43C, P51L, D58A, Y84D, T186K, T342K, and A381P.		
1	30. A kit for determining the ability of a Mycobacterium tuberculosis		
2	bacterium to oxidize a thioamide, the kit comprising:		
3	(a) a container, and		
Δ	(b) (2-ethyl-pyridin-4-yl)methanol.		

1	31. A kit for determining the ability of a Mycobacterium tuberculosis
2	bacterium to oxidize a thioamide, the kit comprising:
3	(a) a container, and
4	(b) radiolabeled ethioamide.
1	32. A kit for determining the ability of a Mycobacterium tuberculosis
2	bacterium to oxidize a thioamide or thiocarbonyl, the kit comprising:
3	(a) a container, and
4	(b) an antibody which specifically binds to a product of a EtaA gene
5	selected from the group consisting of a wild-type EtaA gene (SEQ ID NO:1) and a
6	mutated EtaA gene.
1	33. A kit for determining the ability of a Mycobacterium tuberculosis
2	bacterium to oxidize a thioamide, the kit comprising:
3	(a) a container, and
4	(b) an antibody which specifically binds to (2-ethyl-pyridin-4-
5	yl)methanol.